Nexplanon does initially suppress estrogen (estradiol) production, but the effect is temporary and partial. Within about six months of insertion, estradiol levels typically climb back to near-normal ranges, even while the implant continues preventing pregnancy. That pattern surprises many people who assume a progestin-only method must keep estrogen chronically low for the full three years of use. The reality is more nuanced, and the distinction matters for understanding side effects, bone health, and what to expect over the life of the implant.
How Nexplanon Affects Estrogen in the Body
Nexplanon releases a steady stream of etonogestrel, a synthetic progestin, from a small rod placed under the skin of the upper arm. It does not contain any estrogen. Its primary job is to prevent ovulation by suppressing signals from the brain to the ovaries. Early on, this suppression dampens follicular development, which is the process by which the ovaries grow and mature eggs each cycle. Because growing follicles are the main source of estradiol in premenopausal women, less follicular activity means less estradiol production, at least initially.
The implant works partly through suppression of the hypothalamic-pituitary-ovarian axis, the hormonal feedback loop connecting the brain and ovaries.1PubMed Central. Endometrial effects of etonogestrel (Implanon) contraceptive implant But this suppression is not absolute. Unlike combined hormonal contraceptives that contain both estrogen and progestin and tend to keep ovarian activity quite flat, Nexplanon allows ovarian function to gradually resume in a limited way. Follicles begin developing again, even though they rarely reach full maturity and release an egg. That partial follicular activity is enough to bring estradiol production back up.
The Timeline of Estrogen Recovery
Research on the pharmacology of the etonogestrel implant shows that although it initially suppresses follicular development and estradiol production, ovarian activity slowly increases after about six months. By that point, both follicle-stimulating hormone (FSH) and estradiol levels are almost normal.2European journal of contraception & reproductive health care. The pharmacokinetics and pharmacodynamics of Implanon®, a single-rod etonogestrel contraceptive implant This is a crucial detail: the implant remains highly effective at preventing pregnancy throughout its use, but it does so without keeping estrogen chronically suppressed for three years.
A three-year follow-up study reinforced this picture. Researchers tracking women using the etonogestrel implant found no statistically significant difference between estradiol levels at the start and at the end of the three-year period.3Taylor & Francis Online. Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up) FSH and LH levels were similarly unchanged over that time. In other words, after the initial dip, estrogen levels essentially returned to where they started and stayed there for the remainder of the implant’s life.
This matters because it means the hormonal environment on Nexplanon is quite different from what you might expect if you thought of it as “shutting down” the ovaries. The contraceptive effect relies heavily on thickening cervical mucus and preventing full ovulation, not on maintaining a low-estrogen state.
Why Some People Still Feel Like Their Estrogen Is Low
Despite the evidence that estradiol levels recover, some Nexplanon users report symptoms that overlap with what you would see in a low-estrogen state: vaginal dryness, reduced libido, mood changes, or even hot flashes. These complaints are real, and they deserve attention, even if average estradiol levels in studies look reassuring.
A few things can explain this disconnect. First, averages obscure individual variation. Some women may have more persistent suppression of follicular activity than others, keeping their personal estradiol levels lower for longer. The studies showing near-normal estradiol by six months describe a population trend, not a guarantee for every individual. Second, estradiol is not the only hormone affected. The three-year follow-up study that found stable estradiol also found that prolactin levels increased significantly over three years, although they remained within normal clinical ranges.4Taylor & Francis Online. Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up) Meanwhile, another study found that sex hormone-binding globulin and testosterone levels decreased significantly in implant users.5PubMed Central. Implanon use lowers plasma concentrations of high-molecular-weight adiponectin Lower free testosterone could contribute to reduced libido independently of estrogen levels.
For vaginal dryness specifically, the medical literature acknowledges that progestin-only methods can create a localized low-estrogen environment in the vaginal tissue even when systemic estradiol is adequate. Treatment options for this include low-dose vaginal estrogen, lubricants, and moisturizers.6PubMed Central. Impact of Contraception on Female Sexual Function If you are experiencing vaginal dryness on Nexplanon, this is worth bringing up with your provider because it is a treatable symptom, not something you have to simply tolerate.
Bone Health and the Estradiol Threshold
One of the most practical reasons to care about whether Nexplanon lowers estrogen is bone health. Estrogen plays a critical role in maintaining bone density, and chronic low estrogen is a well-known risk factor for bone loss. This is the reason injectable progestins like medroxyprogesterone acetate (the Depo-Provera shot) carry FDA warnings about bone density: that method suppresses estradiol much more deeply, often to levels seen in menopause.
Nexplanon appears to be in a different category. A review of bone health in estrogen-free contraception found that progestin-only methods leading to estradiol levels between about 30 and 50 picograms per milliliter do not seem to accelerate bone loss.7PubMed Central. Bone health in estrogen-free contraception The etonogestrel implant generally keeps estradiol within or near that range after the initial adjustment period, which is consistent with the finding that implant users do not show the same bone-density concerns as women on injectable progestins. This is one of the practical advantages of the implant’s partial, rather than profound, suppression of ovarian activity.
If you are someone at elevated baseline risk for osteoporosis, due to family history, low body weight, or other medical factors, the distinction between Nexplanon and the injectable shot is worth discussing with your clinician. The two methods are often lumped together as “progestin-only,” but their effects on estrogen and, downstream, on bone differ meaningfully.
The First Few Months Are the Exception
The most honest answer to “does Nexplanon lower estrogen” is that it does, but mainly at the beginning. The first one to six months tend to be when ovarian suppression is strongest and estradiol is lowest. This is also the window when many users experience the most noticeable side effects: irregular bleeding, mood shifts, and sometimes symptoms that mimic low estrogen. For some people, those early months are rough enough that they request removal before the implant has had time to settle.
This is an underappreciated point in patient counseling. If you are told that “Nexplanon does not lower estrogen” as a blanket statement, and then you experience symptoms consistent with low estrogen in the first three months, you might feel dismissed or confused. The more accurate framing is that the implant transiently lowers estradiol, which usually recovers within about half a year. If early side effects are manageable, they often improve on their own as ovarian activity partially rebounds.
Drug Interactions That Could Change the Hormonal Picture
One underappreciated wrinkle is how certain medications interact with Nexplanon’s hormone levels. Etonogestrel is metabolized through a liver enzyme pathway called CYP3A4. Drugs that rev up this pathway, known as enzyme inducers, can speed up how quickly your body breaks down etonogestrel. This effectively lowers the amount of active progestin in your system, potentially weakening the implant’s ability to suppress ovulation and its downstream effects on estrogen.
An analysis of contraceptive failure reports found that in the presence of metabolic inducers that increase the clearance of hormonal agents, implants may be more susceptible than oral contraceptives because they deliver a lower systemic dose to begin with.8Contraception. Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system Common CYP3A4 inducers include certain anti-seizure medications, rifampin (used for tuberculosis), and some antiretroviral drugs. If you take any of these, the implant’s hormonal effects, including its initial suppression of estrogen, could be altered in unpredictable ways. Your provider may recommend an alternative contraceptive method or additional precautions.
How Nexplanon Compares to Combined Methods
It is worth putting Nexplanon’s estrogen effects in context against combined hormonal contraceptives, the pills, patches, and rings that contain both synthetic estrogen and progestin. Combined methods deliberately supply estrogen from outside the body while suppressing the ovaries’ own production. The net result is a relatively stable estrogen environment, which is why combined methods tend to produce predictable withdrawal bleeds and fewer low-estrogen symptoms.
Nexplanon takes a fundamentally different approach. It supplies only progestin and lets the ovaries handle estrogen on their own, to whatever degree the progestin allows. Early on, that means less estrogen than combined methods deliver. Over time, as ovarian activity partially resumes, estrogen levels on the implant are lower than what you would get from a combined pill (which supplies synthetic estrogen on top of whatever the ovaries produce) but higher than what you would see on the injectable progestin shot, which more heavily suppresses the ovaries.
This middle-ground position is part of why Nexplanon has a different side-effect profile from both combined methods and the injectable. It avoids the estrogen-related risks of combined contraceptives, like blood clots and migraines with aura, while also avoiding the deep estrogen suppression that makes the injectable shot a concern for bone health. For many users, this is a favorable tradeoff. For others, the partial and fluctuating nature of ovarian activity on the implant means less hormonal predictability, which can show up as irregular bleeding, mood variability, or intermittent low-estrogen symptoms that come and go.
Irregular Bleeding and What It Tells You About Your Hormones
The most common reason people consider having Nexplanon removed early is unpredictable bleeding. While this is often described as a side effect of progestin acting on the uterine lining, it also reflects the implant’s fluctuating suppression of ovarian activity. The etonogestrel implant exerts complex effects on the endometrium through both direct progestin stimulation and indirect effects from changes in the ovarian hormone environment.9PubMed Central. Endometrial effects of etonogestrel (Implanon) contraceptive implant
In practical terms, when ovarian follicles start developing again (producing some estradiol) and then don’t fully ovulate, the uterine lining gets mixed signals. Some estrogen builds it up, while progestin from the implant keeps it thin and fragile. This mismatch can cause spotting, prolonged light bleeding, or occasionally heavier breakthrough bleeding. The pattern tends to be most erratic in the first year and often settles down as the body reaches a new hormonal equilibrium. For some people, bleeding becomes very light or stops altogether. For others, it remains irregular throughout the implant’s life.
If your bleeding pattern changes dramatically, say from persistent spotting to no bleeding at all or vice versa, that shift often reflects a change in how much follicular activity your ovaries are producing at that moment. It does not necessarily mean something is wrong, but a sudden change after a long stable period is worth mentioning to your provider.
Metabolic Effects Beyond Estrogen
People often focus on estrogen when they think about Nexplanon’s hormonal effects, but the metabolic picture is broader. The three-year follow-up study that found stable estradiol levels also found statistically significant increases in cholesterol, triglycerides, and prolactin over the same period, along with a decrease in creatinine. All of these changes remained within normal clinical ranges.10Taylor & Francis Online. Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up) Fasting blood glucose, LDL, HDL, thyroid hormones, and liver enzymes did not change significantly.
The cholesterol and triglyceride shifts are modest and likely a direct effect of etonogestrel rather than a consequence of changes in estrogen. Progestins as a class can influence lipid metabolism, and etonogestrel is no exception. For most users, these changes are clinically insignificant and do not require intervention. If you already have a condition like familial hypercholesterolemia or very high baseline triglycerides, your clinician may want to monitor lipid panels periodically while you use the implant.
The decrease in sex hormone-binding globulin and testosterone observed in implant users is another metabolic consequence that is not driven by estrogen changes per se.11PubMed Central. Implanon use lowers plasma concentrations of high-molecular-weight adiponectin Lower SHBG is an expected effect of progestin-only exposure without the counterbalancing influence of exogenous estrogen (since combined pills tend to raise SHBG). The drop in testosterone may partially explain reports of decreased libido, though sexual function is complex and influenced by many factors beyond a single hormone level.
When Estrogen Suppression Might Be Prolonged
While the typical trajectory is estrogen recovery within six months, certain situations could prolong the initial suppression. Adolescents whose hypothalamic-pituitary-ovarian axis is still maturing may experience different patterns of recovery than adults. People with very low body weight or those under significant physiological stress already have suppressed ovarian function at baseline, and adding the implant’s progestin could compound that suppression. And as mentioned earlier, concurrent use of CYP3A4-inducing medications can alter the implant’s hormonal dynamics in ways that are not fully predictable.
Breastfeeding is another context where estrogen levels are naturally suppressed by prolactin. Adding Nexplanon during lactation means two independent sources of ovarian suppression are acting simultaneously. Nexplanon is considered safe during breastfeeding and is commonly used in the postpartum period, but it is worth knowing that estradiol recovery may take longer in this setting simply because the body’s baseline is already low.
If you suspect that low estrogen is contributing to persistent symptoms like vaginal dryness, low mood, or absent periods beyond the first year, a simple blood draw for estradiol can give you a concrete answer. Levels consistently below 30 picograms per milliliter might warrant a conversation about management, whether through localized estrogen treatment, a different contraceptive method, or watchful waiting depending on your overall health picture.